PCH
RLMD icon

Polar Capital Holdings’s Relmada Therapeutics RLMD Stock Holding History

Polar Capital Holdings’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.28M Sell
1,340,428
-74,193
-5% -$518K 0.02% 198
2026
Q1 		$9.85M Buy
+1,414,621
New +$6.69M 0.04% 186

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital Holdings's RLMD Position: Q2 2026 in Review

Polar Capital Holdings reduced its Relmada Therapeutics (RLMD) stake by 5.2% in Q2 2026, selling an estimated $518K and leaving 1,340,428 shares worth $9.28M. The position accounts for 0.02% of the portfolio, ranked #198.

Polar Capital Holdings first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.85M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Polar Capital Holdings held 1,340,428 shares of Relmada Therapeutics worth $9.28M as of Q2 2026.
  • Polar Capital Holdings sold 74,193 Relmada Therapeutics shares in Q2 2026, an estimated $518K.
  • Relmada Therapeutics made up 0.02% of Polar Capital Holdings's portfolio in Q2 2026, its #198 holding.
  • Polar Capital Holdings first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Polar Capital Holdings's Relmada Therapeutics position peaked at $9.85M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.